DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Neutral impactCompany

Dr. Reddy's Laboratories Limited — Press Release

NSE 1 hr ago·1 Aug 2026, 4:13 am

DR. Reddy S Laboratories

Dr. Reddy's Laboratories has informed stock exchanges that it has released a formal disclosure on August 01, 2026. This press release is made under SEBI's Regulation 30, which requires listed companies to promptly announce any material information that could impact their stock price.

For investors, this disclosure is significant because it signals that the company has important news to share. While the specific details of the release are not yet public, such filings often relate to regulatory approvals, corporate developments, or financial updates that could influence the company's future performance.

Investors should monitor the official press release for more context. Keeping an eye on how the market reacts to this news will be key to understanding the potential impact on Dr. Reddy's stock.